Evidence map›Paper›PMID 24914142›Full record

ReviewBlood2014

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Boglarka Gyurkocza, Brenda M Sandmaier

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07709195 (Chlorophyllin as an Adjunct for Reducing Oral Mucositis in Myeloablative Total Body Irradiation), which is not on this map. Cited by 307 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
307citing papers in PubMed, 8 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07709195 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Chlorophyllin as an Adjunct for Reducing Oral Mucositis in Myeloablative Total Body Irradiation

TypeinterventionalSponsorTata Memorial CentreRan2024 to 2027Enrolled17ConditionsOral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)ArmsSodium Copper Chlorophyllin
3 · Its place in the literature

Who cites it

307 citing papers in PubMed, 8 syntheses or guidelines pooled it, 583 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Impact of CD34European journal of haematology · 2026
    Article
  19. Article
  20. Article

247 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Boglarka GyurkoczaMemorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College of Cornell University, New York, NY;
Brenda M SandmaierFred Hutchinson Cancer Research Center, Seattle, WA; and University of Washington School of Medicine, Seattle, WA.ORCID http://orcid.org/0000-0002-9767-9739
Memorial Sloan Kettering Cancer Center · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
NCI NIH HHS CA015704NCI NIH HHS CA018029NCI NIH HHS CA078902NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early regimens relied on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and reinfusion of the graft would then restore hematopoiesis. However, as the contribution of graft-versus-tumor effects to the success of allogeneic HCT was recognized over time, in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. This resulted in a major paradigm shift, and consequently, the pool of eligible patients underwent a remarkable expansion. In this article, we provide a review of the definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. We also provide a brief review of the toxicities associated with these regimens.

Indexed as

AllograftsAntilymphocyte SerumAntineoplastic Combined Chemotherapy ProtocolsAutograftsClinical Trials as TopicHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansMyeloablative AgonistsRadioimmunotherapyTransplantation ConditioningWhole-Body IrradiationAntilymphocyte SerumMyeloablative Agonists

Identifiers

PMID24914142
PMCPMC4102707
OpenAlexW1996320020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.